MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data
Min Lu(South China Agricultural University), Ming Huang(Central South University), Yue Pan(Shandong University), Ping Liu(Ministry of Education and Child Care), Chunhong Hu(Central South University), Fang Wu(Central South University), Fang Ma(Harbin Institute of Technology), Xianling Liu(Central South University), Chao Deng(Central South University), Long Shu(Central South University)
Cited by 24
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
|Clinical Epigenetics|2021|253
Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis
|Molecular & Cellular Proteomics|2007|247